Providence Capital Advisors, LLC Fate Therapeutics Inc Transaction History
Providence Capital Advisors, LLC
- $445 Million
- Q1 2024
A detailed history of Providence Capital Advisors, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Providence Capital Advisors, LLC holds 61 shares of FATE stock, worth $200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61
Previous 61
-0.0%
Holding current value
$200
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding FATE
# of Institutions
178Shares Held
124MCall Options Held
222KPut Options Held
48.6K-
Redmile Group, LLC San Francisco, CA13.2MShares$43.2 Million3.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.91MShares$32.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.1MShares$29.8 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA8.22MShares$26.9 Million3.14% of portfolio
-
State Street Corp Boston, MA8.04MShares$26.4 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $318M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...